Pirfenidone: A Promising Drug in Ocular Therapeutics.

Arpon Biswas, Sristi Agrawal, Amol Chhatrapati Bisen, Sachin Nashik Sanap, Rabi Sankar Bhatta, Anjali Mishra, Neeraj Mohan Gupta, Ramakrishna Rayiti

Journal: Chemistry & biodiversity 2024;21(3):e202301389

PMID: 38299764

Full Text on Wiley View on PubMed

Abstract

Pirfenidone, initially indicated for lung fibrosis, has gone beyond its original purpose, and shown promise in eye care. This detailed review tracks its evolution from lung treatment to aiding eye healing as evidenced by published literature. Pirfenidone's multifaceted attributes extend to mitigating corneal fibrosis, inflammation, and trauma. Through rigorous investigations, its efficacy emerges in diabetic retinopathy, macular degeneration, and postoperative glaucoma interventions. As an unheralded protagonist, pirfenidone reshapes ocular care paradigms, inviting renewed research opportunities.

Address: Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.; Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, 201002, India.; Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.; Department of Chemistry, Government P. G. College, Guna, Madhya Pradesh, 473001, India.

DOI: 10.1002/cbdv.202301389

Link outs

Free resources

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-HLA-B-1

Subscription / membership required

Full Text Sources:

https://doi.org/10.1002/cbdv.202301389

MeSH Terms: Wound Healing, Pyridones